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Background and Aims: During fibrosis hepatic stellate cells (HSC) undergo activation,
proliferation, and senescence but the regulation of these important processes is poorly
understood. The adenosine A2A receptor (A2A) is known to be present on HSC, and its
activation results in liver fibrosis. In this study, we tested if A2A has a role in the regulation
of HSC proliferation, apoptosis, senescence, and the relevant molecular mechanism.
Methods: The ability of adenosine to regulate p53 and Rb protein levels, proliferation,
apoptosis and senescence was tested in the human HSC cell line LX-2 and rat primary
HSC.
Results: Adenosine receptor activation down-regulates p53 and Rb protein levels,
increases BrdU incorporation and increases cell survival in LX-2 cells and in primary
rat HSC. These effects of NECA were reproduced by an adenosine A2A receptor
specific agonist (CGS21680) and blocked by a specific antagonist (ZM241385). By day
twenty-one of culture primary rat HSC entered senescence and expressed β-gal which
was significantly inhibited by NECA. Furthermore, NECA induced down regulation of p53
and Rb and Rac1, and decreased phosphorylation of p44-42 MAP Kinase in LX-2 cells and
primary rat HSC. These effects were reproduced by the cAMP analog 8-Bromo-cAMP, and
the adenylyl cyclase activator forskolin, and were blocked by PKA inhibitors.
Conclusions: These results demonstrate that A2A receptor regulates a number of HSC
fate decisions and induces greater HSC proliferation, reduces apoptosis and senescence
by decreasing p53 and Rb through cAMP-PKA/Rac1/p38 MAPK pathway. This provides a
mechanism for adenosine induced HSC regulation and liver fibrosis.
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INTRODUCTION
Activation of hepatic stellate cells (HSC) is recognized as a vital
step in liver fibrosis and results in the acquisition ofmultiple func-
tions including contraction, chemotaxis and matrix remodeling
(Kawada et al., 1992; Rockey, 1995; Watanabe et al., 2007; Soon
and Yee, 2008; Mohamadnejad et al., 2010). During fibrosis the
activated HSC population is simultaneously undergoing prolif-
eration, apoptosis and senescence (Houglum et al., 1997; Knittel
et al., 1997; Iredale et al., 1998; Iredale, 2001; Krizhanovsky et al.,
2008a). The induction of proliferation is an early step after HSC
activation and is stimulated by a number of cytokines includ-
ing platelet derived growth factor (PDGF) (Pinzani et al., 1989;
Kinnman et al., 2001). HSC are also undergoing apoptosis dur-
ing the progression of fibrosis and this increases during fibrosis
resolution (Reinehr et al., 2008). Overall HSC are resistant to the
Abbreviations: AR-A1, adenosine receptor A1; AR-A2A, adenosine receptor A2A;
AR-A2B, adenosine receptor A2B; AR-A3, adenosine receptor A3; β-gal; beta-
galactosidase; cAMP, cyclic adenosine monophosphate; HSC, hepatic stellate cells;
NECA, 5′-N-Ethylcarboxamide adenosine; PKA, protein kinase A; SA-β-Gal, senes-
cence associated β-galactosidase.
usual initiators of apoptosis such as CD95-L and oxidiative stress,
and in vivo HSC apoptosis is induced by natural killer cells and
Kupffer (Fischer et al., 2002; Radaeva et al., 2006).
The central features of senescence is irreversible growth arrest,
an enlarged cellular morphology and expression of senescence-
associated beta-galactosidase (SA-Bgal) (Hayflick, 1965; Dimri
et al., 1995; Campisi, 2011). Although cellular senescence was first
described in 1965 in normal human cells in culture its occur-
rence in vivo was only confirmed recently when it was shown that
the fibrotic liver contains a number of senescent cells, and these
were identified to be predominantly HSC (Krizhanovsky et al.,
2008b). Furthermore if HSC were genetically modified to stop the
development of senescence, they continued to proliferate result-
ing in increased fibrosis. The development of senescence is known
to be dependent on the p16-Rb and Arf-p53-p21 pathways, and
the modulation of these pathways can regulate cellular senescence
(Abriss et al., 2003; Campisi and d’Adda di Fagagna, 2007).
The decision of HSC fate between proliferation, apoptosis
and senescence clearly has a very significant effect on the devel-
opment of fibrosis, yet little is known about how the entry of
www.frontiersin.org April 2014 | Volume 5 | Article 69 | 1
Ahsan and Mehal Adenosine in senescence
HSC between these three different states is regulated. A cen-
tral pro-fibrotic role of adenosine via the A2 receptor has been
identified, and adenosine results in increased production of col-
lagen and transforming growth factor-β (Chan et al., 2006; Che
et al., 2007; Sohail et al., 2009). The in vivo significance of adeno-
sine is shown by the fact that mice lacking the A2A receptor
have reduced liver fibrosis(Chan et al., 2006). Because of this
we hypothesized that adenosine may be an important regula-
tor of HSC fate. Adenosine is very well suited for regulating
HSC fate decisions as it is produced rapidly in the local envi-
ronment in response to cell stress and damage, and has a very
short half-life (Feoktistov et al., 2009; Chan and Cronstein,
2010).
This study demonstrates that adenosine, via the A2A recep-
tor down-regulates p53, and Rb and enhances proliferation of
HSC cell lines and primary cells. This is associated with a reduc-
tion in HSC apoptosis, and senescence by via a PKA/Rac1/P38
MAPK pathway. This places adenosine as a key regulator of




Pan adenosine receptor agonist 5′-N-Ethylcarboxamide adeno-
sine (NECA), an analog of cAMP 8-Bromoadenosine 3′:5′-cyclic
monophosphate (8-Bromo-cAMP), an adenylyl cyclase activa-
tor forskolin, and a PKA inhibitor H-89 dihydrochloride hydrate
Sigma-Aldrich (St. Louis, MO). Adenosine receptor A2A receptor
antagonist ZM241385 and agonist CGS21680 Tocris Bioscience
(Minneapolis, MN). Myristoylated PKA inhibitor 14–22 amide
was purchased from Calbiochem (La Jolla, CA).
LX-2 CELL CULTURE
Human immortalized hepatic stellate cell line, LX-2 have been
previously described (Xu et al., 2005). Cells were cultured in high
glucose (4.5g/L D-Glucose) containing Dulbecco’s modified Eagle
medium (DMEM), 100 IU/ml penicillin, 100mg/ml streptomycin
and 5% fetal bovine serum (Invitrogen). Cells were maintained at
37◦C in a humidified atmosphere with 5% CO2. Culture media
were replaced every 3 days.
Isolation and culture of HSC
Male Sprague-Dawley rats (500–700 g) were used for primary
HSC isolation. Experiments were performed in accordance with
Institutional Animal Care and Use Committee. HSC were isolated
via in situ pronase/collagenase perfusion followed by Opti-Prep
density gradient centrifugation as described previously (Radaeva
et al., 2007). HSC were plated in 10% FBS at a density of 1 × 105
cells/ml and then plated onto 6-well plates in 2.5ml cell suspen-
sion/well. After 12 h, non-adherent cells and debris were removed
by washing with HBSS. Purity of the cultures was assessed by typ-
ical light microscopic appearance at this point. Vitamin A auto
fluorescence was more than 90% (Figures 1A–D).
Western blots
Western blot analysis and immuno-detection was performed by
standard protocols for 2–21 days cultured primary rat HSC
or human HSC cell line LX-2 cells with indicated treatment.
Blots were incubated with primary antibodies against α-smooth
muscle actin (α-SMA; 1:2000; Sigma-Aldrich, St. Louis, MO),
p53 and Rb (1: 1000; BD Phamingen, San Jose, CA), Rac1 (1:
1000; Millipore, Billerica, MA), phospho-p-44/42 MAPK and
p-44/42MAPK (1:1000; Cell Signaling Technology, Danvers, MA)
or β-actin (1:1000; Santa Cruz Biotechnology) for overnight at
4◦C followed by 1 h incubation at room temperature with HRP-
linked IgG secondary antibodies. Blots were visualized by using
a SuperSignal® West Pico chemiluminescent substrate (Thermo
Scientific, Rockford, IL). β-actin was developed as a loading
control. Cell proliferation was determined by 5-bromo-2′-deoxy-
uridine (BrdU) incorporation assay using commercially available
Cell Proliferation ELISA, BrdU (colorimetric) kit from Roche
(Indianapolis, IN).
Annexin V/PI stained flow cytometric analysis of Apoptosis
LX-2 cells were plated (2 × 105 cells/well) in the 6-well plates and
incubated overnight. Cells were treated with indicated reagents
and cultured for 24 h. After the treatment cells were exposed to
H2O2 (100μM) for 5 h. Dead cells were quantified by annexin
V-FITC-propidium iodide (PI) double staining, using Annexin V-
FITC Apoptosis Detection Kit II (BD Biosciences). Experimental
analysis was performed on FACS Calibur (BD, Arlington, MA)
and the results were analyzed usingWinMDI 2.9 Software (Joseph
Trotter).
Senescence-associated β-galactosidase (SA-β-Gal) Staining
Rat primary HSC were cultured in the 6 wells plate and SA-
β-Gal staining was performed using a senescence detection kit
(Calbiochem, La Jolla, CA). Cells were fixed in β-galactosidase
fixative solution, washed with PBS and incubated overnight at
37◦C with freshly prepared SA-β-Gal staining solution: 1mg of
5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal)/ml (stock
solution: 20mg/ml in dimethylformamide) in staining solution
with staining supplement. Thereafter cells were washed with PBS
and β-galactosidase-positive cells were counted under bright field
illumination using Image-J cell counting software.
Statistics
All data were shown as means ± s.e.m. Statistical significance
were analyzed with unpaired student t-test using GraphPad
Prism software (Version 5.0). P value is < 0.05 was taken as
significant.
RESULTS
MORPHOLOGICAL CHANGES OF PRIMARY RAT HSC DURING
EXTENDED CULTURE
HSC activation is characterized by gradual loss of retinoic acid
and lipid stores, expansion of cytoplasm and gradual conver-
sion to myofibroblasts leading to increase expression of α-smooth
muscle actin (α-SMA) (Bataller et al., 2005; Friedman, 2008). We
confirmed this in the in vitro culture of HSC on plastic. Day-2
after isolation HSC had the typical rounded and bright appear-
ance (Figure 1A) and became gradually activated, with reduction
in the retinoic acid and lipid droplets, expansion of cytoplasm
by day-10 (Figure 1B), finally becoming large flatted myofibrob-
lastic phenotype by day-21 (Figure 1C). These morphological
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FIGURE 1 | Pan-adenosine receptor agonist (NECA) down regulates
p53 and Rb level in HSC through adenosine receptor A2A signaling.
Morphological characteristics of primary rat HSC were recorded for 2–21
days in the culture and shown (A) at day-2 in quiescent stage, (B) at
day-10 in activated stage, or (C) at day-21 in highly activated stage. (D)
Western blot shows expression of α-smooth muscle actin (α-SMA) at
day-2 and at day-21 as a marker of activated primary HSC. Human HSC
line LX-2 cells were treated for 2 days with or without 10μM of NECA
in presence or absence of either an A2A receptor antagonist ZM241385
(10μM) or agonist CGS21680 (10μM). The control cells (CTL) were
treated with DMSO. Primary rat HSC were similarly treated with NECA,
ZM241385 and, or CGS 21680 for 5 days after 10 days normal culture (at
the activated stage). (E–G) Western blots of p53 and Rb are shown for
LX-2 (F–H) and primary rat HSC.
changes were confirmed by assaying for the expression of α-
SMA protein levels at day-2 and day-21. α-SMA was virtually
absent at day-2, and had become highly upregulated by day-21
(Figure 1D).
NECA SUPPRESSES p53 AND Rb IN LX2 AND PRIMARY HSC THROUGH
ACTIVATION OF ADENOSINE RECEPTOR A2A
Since the expression of p53 and Rb levels are important ini-
tiator of senescence we analyzed their expression and pro-
tein level with or without treatment with the pan-adenosine
receptor agonist NECA (Ben-Porath and Weinberg, 2005;
Krizhanovsky et al., 2008b). NECA (10μM) suppressed the
expression of p53 and Rb protein levels in LX-2 (Figure 1E)
and primary rat HSC (Figure 1F). Inhibition of p53 and
Rb protein levels were reproduced by an A2A receptor ago-
nist (CGS21680 10μM), and the ability of NECA to inhibit
p53 and Rb protein levels were blocked by an A2A recep-
tor antagonist (ZM241385 10μM) in LX-2 (Figure 1G) and
primary rat HSC (Figure 1H). This demonstrates that p53
and Rb protein down-regulatory effects by NECA are through
A2Areceptor and its downstream signaling cascades. Furthermore,
the slight upregulation of p53 and Rb protein levels in the
presence of A2A antagonist (Figures 1G,H) suggests that back-
ground levels of adenosine are functional in the usual tissue
culture.
NECA ENHANCES CELL PROLIFERATION THROUGH ACTIVATION OF
ADENOSINE RECEPTOR A2A IN THE LX-2 CELLS AND PRIMARY RAT
HSC
The ability of the pan-adenosine agonist NECA to downregu-
late p53 and Rb protein levels predicts that NECA will induce
HSC proliferation. When tested NECA significantly increased
cell proliferation by 0.971 ± 0.125 and 0.233 ± 0.015 over a
24 h period (p value = 0.001) in LX-2 (Figure 2A) and primary
rat HSC (Figure 2B) respectively. This response was reproduced
by an A2A receptor specific agonist (0.93 ± 0.055 in LX-2 and
0.207 ± 0.006 in primary rat HSC), and completely blocked by
an A2A receptor antagonist in both LX-2 and primary rat HSC
(Figures 2A,B).
NECA INHIBITS H2O2-INDUCED CELL DEATH IN THE LX-2 CELLS
HSC apoptosis is known to be a limiting mechanism for liver
fibrosis. H2O2 provides a severe oxidative stress that induces
HSC death. NECA-pretreated HSC were significantly resistant
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FIGURE 2 | NECA enhances BrdU incorporation and decreases
H2O2-induced cell death in HSC through activation of adenosine
receptor A2A. LX-2 cells or 10 days in-vitro cultured primary rat HSC
were treated with pan adenosine receptor agonist NECA (10μM), an A2A
receptor antagonist (ZM241385 10μM), or an A2A receptor agonist
(CGS21680 10μM) for 24 h and measured BrdU incorporation. The
level of BrdU incorporation was shown in (A) LX-2 cells (∗ = 0.0126,
§ = 0.00099, ¶ = 0.00428) and in (B) primary rat HSC (∗ = <0.001,
§ = <0.001, ¶ = < 0.001). LX-2 cells were treated (C) with vehicles
DMSO, (D) NECA (10μM), (E) an A2A receptor antagonist (ZM241385
10μM), or, (F) ZM241385 (10μM) plus NECA (10μM), or, (G) with an
A2A receptor agonist CGS21680 (10μM) for 24 h followed by 100μM of
H2O2 for 5 h. (H) Viable and dead cells were quantified by both Annexin
V and PI staining flow-cytometry (paired symbols mark comparisons with
significance greater than P of 0.05). (∗ = 0.0084, § = 0.0017, ¶ = 0.0017,
# = 0.0084).
to H2O2 induced cell death. Data showed that 100μM of
H2O2 induced apoptosis by 5 h in control LX-2 (Figure 2C)
which was inhibited by pretreatment with 10μM of NECA
(Figure 2D). A similar inhibition of H2O2-induced apoptosis was
observed by the pretreatment with A2A receptor agonist (10μM)
(Figure 2G). Pretreatment with an A2A receptor antagonist
significantly enhanced LX-2 cell apoptosis by 100μM H2O2
compared to vehicle treated cells (Figure 2E). Furthermore,
pretreatment with an A2A receptor antagonist in addition to
NECA significantly interfered with the ability of NECA-induced
cellular survival against H2O2 (Figure 2F). Data were quanti-
fied by annexin V and propidium iodide (PI) staining FACS
analysis in the Figure 2H. Long term culture of primary rat
HSC (60 days) in the presence of NECA (10μM) signifi-
cantly enhanced cellular longevity compared to vehicle (DMSO)-
treated cells (Supplemental Figure 1A), data were quantified
in the Supplemental Figure 1B using Image-J cell count soft-
ware. This demonstrates that NECA induced activation of A2A
receptor reduces HSC death in the presence of severe oxidative
stress.
NECA SUPPRESSES SENESCENCE AND SENESCENCE-INDUCING
MARKERS p53 AND Rb IN THE PRIMARY RAT HSC
Cellular senescence is a potent barrier to tumorigenesis and lim-
its tumor cell proliferation and tumor evolution (Serrano et al.,
1997; Schmitt et al., 2002; Braig et al., 2005; Krizhanovsky et al.,
2008a). Moreover senescence of activated HSC limits prolifera-
tion thereby limiting liver fibrosis by down regulating production
of extra cellular matrix (Krizhanovsky et al., 2008b). At day-2
of culture there was no SA-β-gal expression in primary rat HSC
(Figure 3A). By day 21 of normal culture HSC had entered senes-
cence (Figure 3B) up to 67.41 ± 6.11% (Figure 3C) as detected
by SA-β-gal expression. This was supported by the very high
level of expression of p53 and Rb at day-21 of culture com-
pared with day-2 (Figure 3D). Treatment of HSC with 10μM
NECA for 21 days significantly reduced the degree of senescence
to 29.60 ± 5.6% (Figures 3F,G) from 79.2 ± 4.9%, in control
cells (Figures 3E–G; p value ≤ 0.001). NECA resulted in down
regulation of both p53 and Rb (Figure 3H) at day 21 of culture.
For the LX-2 cell line after 40 passages senescent LX-2 cells were
detected with or without DMSO (Supplemental Figures 2A,B),
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FIGURE 3 | NECA suppresses senescence by down regulating p53 and
Rb in the primary rat HSC. Cells were cultured for 2–21 days and
senescence detected using SA-β-Gal staining (A) at day-2 or (B) at day-21,
and (C) the number of senescent cells quantified (∗ = significant but p
value is not applicable because first column is totally zero). (D) Western
blot analysis of p53 and Rb level in the normal culture at the day-2 or,
day-21. Similarly senescence was detected in the HSC treated (E) with
vehicle DMSO, or (F) with NECA for 21 days. (G) The number of
senescence cells was quantified in the cells treated with DMSO (CTL) or,
with NECA for 21 days using Image-J cell count software (∗ = <0.001).
(H) Western blot analysis of p53 and Rb level in the cells treated with
DMSO (CTL) or, with NECA for 21 days.
however we were unable to detect any senescent LX-2 cells in
either passages-2 (Supplemental Figure 2A) or NECA treated
passages-40 (Supplemental Figure 2B).
NECA SUPPRESSES p53 AND Rb THROUGH PKA/Rac1/p38MAPK
SIGNALING CASCADES IN THE LX-2 CELLS AND PRIMARY RAT HSC
We next wished to identify the pathway between A2A recep-
tor and the p53 and Rb signaling cascades to understand how
NECA mediates its regulation of HSC. In other systems NECA
exerts its effect via Gαs-dependent activation of adenylyl cyclase
resulting in an increased cytosolic cAMP followed by activation
of PKA (Grant et al., 1999, 2001). We used 8-Bromo-cAMP,
an analog cAMP which is a known activator of PKA, and an
adenylyl cyclase activator forskolin to test whether by activa-
tion of adenylyl cyclase, cAMP and PKA can reproduced the
downregulation of p53 and Rb, which is showed by the treat-
ment of NECA. Treatment with 8-Bromo-cAMP (1mM) and
forskolin (50μM) both down regulated the expression of p53
and Rb in LX-2 (Figure 4A) and primary rat HSC (Figure 4B).
This demonstrates that the known adenylyl cyclase/cAMP/PKA
pathway downstream of A2A receptor is able to induce down-
regulation of p53 and Rb. We further confirmed this pathway
by using pharmacologically available PKA inhibitors PKi 14–22
amide (10μM) or H-89 dihydrocloride hydrate (25μM). Both
PKA inhibitors blocked the suppression of p53 and Rb by NECA
(Figure 4). It is also known that the activation of p38 MAPK
results in accumulation of p53 and Rb protein level, resulting in
senescence (Wang et al., 2002). We checked whether the NECA,
8-Bromo-cAMP, or forskolin-mediated down regulation of p53
and Rb were from deactivation of p38 MAPK and/or down reg-
ulation of upstream of p38 MAPK, Rac1. Figure 4 shows that
NECA, 8-Bromo-cAMP, or forskolin down regulated the protein
level of Rac1 and phosphorylation of p44/42 MAPK. This down-
regulation by NECA was blocked by additional treatment of the
PKA inhibitor PKAi or H-89. These data show that activation of
AR-A2A by NECA down regulates the p53 and Rb level through
PKA/Rac1/p38 MAPK pathway (Figure 4C).
DISCUSSION
Adenosine is recognized as having an important role in HSC
differentiation and liver fibrosis (Cronstein, 2004; Chan et al.,
2006; Sohail et al., 2009; Chan and Cronstein, 2010). In response
to adenosine, HSC up-regulate collagen and transforming growth
factor, and inhibition of the adenosine A2A receptor signaling
decreases liver fibrosis in vivo (Chan et al., 2006; Chunn et al.,
2006; Che et al., 2007). We have also recently demonstrated that
adenosine inhibits platelet-derived growth factor–mediated HSC
chemotaxis (Hashmi et al., 2007). The rapid production of adeno-
sine in sites of tissue injury and hypoxia, coupled with its rapid
removal by ectonucleotidases makes adenosine an excellent mes-
senger to link injury with tissue repair responses. Because of their
anti-fibrotic potential several adenosine receptor antagonists are
in clinical development (Gao and Jacobson, 2007).
After activation HSC undergo rapid proliferation followed by
apoptosis or senescence, and each of these cell fates is impor-
tant at the level of the whole organ (Krizhanovsky et al., 2008b;
Friedman, 2010). For example inhibition of the senescence path-
way by deleting p53 results in fewer senescent HSC, a greater
number of HSC, increased liver fibrosis and slower resolution of
fibrosis (Krizhanovsky et al., 2008b). The in vivo situation is com-
plex because these are simultaneous rather than sequential events.
With the recognition of the important role of HSC proliferation,
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FIGURE 4 | A cAMP analog, or an activator of adenylyl cyclase
Forskolin, or NECA down regulates p53 and Rb through down
regulation of Rac1 and decreased activation of p38 MAPK in the
HSC. LX-2 cells were treated for 2 days, and 10 days cultured activated
primary rat HSC were treated for 5 days with 8-Bromo-cAMP (1mM) or,
Forskolin (50μM) or NECA (10μM) in presence or absence of PKA
inhibitor 12–14 amide (myristoylated; 10μM) or H-89 dihydrochloride
hydrate (25μM). (A) Western blot analysis of p53, Rb, Rac1, and p44/42
MAPK levels in the 2 days treated LX-2 cells. (B) Western blot analysis
of p53, Rb, Rac1, and p44/42 MAPK levels in the 5 days treated
activated rat primary HSC. (C) Summary of adenosine receptor A2A
mediated signaling in the process of senescence in HSC.
apoptosis and senescence in liver fibrosis it becomes important to
ask how these steps are regulated. To address this we examined
the role of adenosine in regulating these different HSC fates. We
initially chose to focus on p53 and p16/Rb tumor suppressor
pathways. The reason for this is that both pathways are central
to the development of senescence and their regulation would
give an early indication if adenosine has a role in senescence
biology (Campisi and d’Adda di Fagagna, 2007; Collado et al.,
2007). P53 promotes senescence by transactivation of a number
of genes that inhibit proliferation (He et al., 2007). P16 inhibits
cyclin-dependent kinases 2 and 4, preventing Rb phosphoryla-
tion and allowing Rb to promote a heterochromatin environment
that silences proliferation associated genes (Narita et al., 2003).
The pan-adenoisne agonist NECA significantly suppressed both
p53 and Rb in the LX-2 cell line as well as primary rat HSC.
The known requirement for the adenosine A2A receptor in liver
fibrosis made it the prime candidate, and was demonstrated to be
responsible for p53 and Rb suppression.
Downregulation of p53 and Rb predicted that adenosine sig-
naling will significantly increase proliferation and reduce apop-
tosis. This was confirmed by quantifying BrdU incorporation
and annexin/PI staining for LX-2 and primary rat HSC. The
specificity of the A2A receptor for proliferation and cell death
was again demonstrated by the use of receptor specific agonists
and antagonists. A previous study has reported that adenosine
signaling does not affect HSC proliferation, however this was lim-
ited to examining cell lines and lower concentrations of agonists
and antagonists (Che et al., 2007). Our results demonstrate that
adenosine downregulated core cell fate pathways of p53 and Rb,
increased HSC proliferation, and reduced HSC apoptosis. The
increase in HSC proliferation, even with a block in cell death,
would not be expected to result in greater HSC number and liver
fibrosis because proliferating cells enter senescence after a variable
number of cell cycles (Hoare et al., 2010). This was demonstrated
to be the case as the majority of primary rat HSC cultured for 21
days entered senescence, and this was associated with an increase
in p53 and Rb. In contrast primary rat HSC cultured for 21 days
in the presence of NECA demonstrated lower levels of p53 and Rb
and significantly less senescence.
The above data set establish an important role for adenosine
in regulating the commitment of a HSC population between pro-
liferation, apoptosis and senescence. Each of these processes has
been shown to be important in HSC biology and liver fibro-
sis, and we propose that by shifting the balance between them
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adenosine has an amplified effect on the overall HSC population
and liver fibrosis. In cells other than HSC IL-6 and IL-8 have
been shown to induce senescence via STAT5 and suppressor of
cytokine signaling (Kuilman et al., 2008). In HSC interleukin-22
has been demonstrated to inhibit HSC activation and apoptosis
but to induce HSC senescence via a STAT3 and SOCS3 mediated
pathway (Kong et al., 2012). Thus IL-22 would limit the num-
bers of HSC entering the activated pool, and would also accelerate
their removal by increasing senescence. Adenosine by contrast
increases the entry of HSC into the activated pool, and keeps them
there by decreasing cell death and senescence.
Adenosine signals via four receptors, A1, A2A, A2B, and A3. Of
these A2A is required for the development of liver fibrosis, which
fits very well with our demonstration of a role for A2A receptors in
the adenosine mediated effects on HSC fate decisions. A stimula-
tory cAMP coupled pathway is known to be present downstream
of A2A receptor. By using a number of stimulators and inhibitors
we have demonstrated that an adenyly cyclase, cAMP, PKA, Rac1,
and p38 pathway is responsible for the downregulation of p53 and
Rb. A number of adenosine antagonists are under clinical devel-
opment as anti-fibrotics and the identification of this pathway
makes available additional targets therapeutic intervention.
In summary we have identified adenosine as the first HSC
anti-senescence factor. In addition adenosine regulates HSC fate
decisions of proliferation and cell death. When coupled with
the known ability of adenosine-A2A receptor to induce HSC
activation and collagen production it explains the pro-fibrotic
qualities of this pathway, and supports prioritizing it as a target
for therapeutic development.
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Supplemental Figure 1 | NECA enhances cellular longevity in the primary
rat HSC. Cells were cultured without (CTL/DMSO) or with 10μM of NECA
for 60 days. (A) Rat primary HSC were cultured for 60 days without (CTL)
or with NECA. (B) The number of viable cells was quantitated using
Image-J cell counts in randomly taken images of 60 days cultured rat
primary HSC without (CTL) or with NECA (10μM) using inverted phase
contrast microscope.
Supplemental Figure 2 | NECA suppresses long-term culture-induced β-Gal
expression in the LX-2 cells. Arrows are indicating expression of β-Gal in
the nucleus of LX-2. (A) β-Gal expression in 2–40 passages normal culture
of LX-2 cells. (B) β-Gal expression in the 40 passages culture of LX-2 cells
treated without (CTL) or with 10μM of NECA.
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